Objective. Finding the human genes co-causing complex diseases,
Introduction
Complex diseases are attributed to multiple heterogeneous causes, and rarely involve abnormalities on a single gene [1] . High-throughput techniques are useful to identify genes likely to be relevant for specific human diseases and can look at genomic regions containing massive amounts of candidate genes. Thus, since the manual verification of individual candidate genes is expensive and time-consuming, computational methods are needed to aid the discovery of disease-genes by ranking candidate genes from the gene sets on the basis of their likelihood of being involved in a certain disease [2] . This problem, called disease-gene prioritization or simply gene prioritization (GP), is nowadays central biomedicine, since knowing the genetic causes of a given disease can help studying effective treatments for the disease itself, in addition to its prevention. This task is challenging and characterized by several issues, including the vast amount and the heterogeneity of the available information, requiring scalable approaches to integrate multiple data sources; the rarity of known disease-genes for most diseases in the existing disease taxonomies (e.g. the OMIM database [3] ); the existence of shared profiles among diseases; the possible association of the same gene with multiple genetic abnormal phenotypes. These difficulties have led to the introduction of numerous categories of study to solve the GP problem.
Text mining approaches attempted in discovering common patterns between genes/proteins and diseases by scanning the literature to find co-occurrences statistically significant [4, 5, 6] . Other proposed tools to discover candidate genes for human genetic diseases relied on genome wide association studies (GWAS), asserting that multiple, common small-risk variants interact to cause common diseases [7, 8, 9, 10] . Each study can look at hundreds or thousands of loci at the same time; nevertheless, this approach tends to produce many falsepositive results (that is detected candidate genes which are not really involved in the disease etiology), and the experimental validation of candidate genes, for instance through resequencing, pathway or expression analysis, is still expensive and time requiring [11] .
Other works leveraged whole exome sequencing to capture all exonic and flanking sequences and to include probes targeting microRNA and other sequences of interest [12] . These studies have reported a successful molecular diagnosis in up to 25% of cases in large cohorts of unselected, consecutive patients [13] . Phenotype-driven analyses of exome data have also been investigated with the aim of filtering out common variants and those deemed to be non-pathogenic [14] .
Within the Network medicine context, alternative approaches have widely employed the so called guilt-by-association (GBA) principle, in which candidate disease genes are ranked by exploiting the assumption that similar genes tend to share similar diseases [15] . They base on gene networks, in which nodes are genes and connections represent precomputed functional relationships among genes, like protein-protein interactions [16] , or transcriptional co-expression regulation [17] . Network-based methods differ from each other in the way they exploit disease-genes and their direct connections, ranging from protein-protein interaction network analysis and semi-supervised graph partitioning [17, 18] , to flow propagation [19] , random walks [20] , kernelized score functions [21] , Gaussian fields and Harmonic functions [22] , multiple kernel learning [23] , regression trees on mutual information gene networks [24] and network weights adjustment according to a given disease [25] . These methods tend to prefer better characterized genes and/or diseases, due to their need of already discovered disease-genes. Thus, in particular where little prior knowledge about diseases is available, the accurate prioritization of putative disease-genes remains a challenge. Actually, thousands of known genetic diseases in the OMIM (Online Mendelian Inheritance in Man) database have no established gene-disease associations [3] .
To partially address this issue, fewer works used tissue-specific expression patterns on the hypothesis that genes responsible for a tissue(s)-specific phenotype are expected to be more expressed in affected than unaffected tissues [26, 27, 28] . However, not considering and integrating potentially complementary evidence coming from other heterogeneous data sources may be a limitation [29] . For instance, interacting pairs of candidate proteins and proteins encoded by known phenotype susceptibility genes (a type of data which also targets rare alleles) can be crucial in prioritizing genes, since two proteins involved in the same biological (dys)function often interact [30] .
For these reasons, several research groups have adopted integrated methodologies to exploit at the same time multiple heterogeneous sources, ranging from functional profiles and expression quantitative trait loci to protein complexes and genetics or physical interactions [26, 29, 31] . General approaches to integrate different information sources rank candidate genes with reference to any single source using various metrics, to combine the obtained ranks in an overall rank [15] . For network-based information sources, an integrated network is constructed by combining the topology of each network into a consensus network more informative and with larger coverage [32] .
Finally, a promising category of GP methods has focused on the analysis of common characteristics among different diseases [33, 34] , discovering sets of interacting proteins and molecular pathways often shared by multiple diseases [35] . The main benefit of such an approach is that 'transferring' information from comparable diseases provides researcher with additional predictive information to prioritize genes, and in particular for less studied abnormalities [36] , thus leading to new therapeutic treatments not previously considered. For instance, shared molecular connections between diabetes and dementia are now fueling research into the possible use of insulin to treat Alzheimer's disease [37] .
Most GP methods mentioned above tend to focus on some of the issues characterizing the gene prioritization problem, thus limiting their generalization abilities to specific data and/or settings. For instance, the class imbalance problem characterizing GP is neglected by most existing approaches: the availability of a very low number of annotated genes (the positive instances) creates a disproportion between positive and negative instances (non-causative genes) which leads to a decay of performance for imbalance-unaware classification algorithms [38, 39] . Indeed, employing imbalance-aware algorithms obtained successful results in similar contexts, like the gene function prediction [40, 41] . Moreover, the majority of proposed techniques tend to prioritize disease-genes focusing on single diseases, limiting in this way the amount of prior information adopted as input and the effectiveness of the provided predictions [42] .
In this study, we present a novel network-based method, named Gene2DisCo (Gene to Disease using Disease Commonalities), for prioritizing candidate disease-genes by taking into account all the issues of the GP problem. A unique feature of Gene2DisCo is indeed the synergy of data source integration, imbalance-aware learning, and exploitation of disease similarities. In particular, our approach extends a couple of methods recently proposed to prioritize genes [43, 44] , by embedding an effective strategy to transfer learning from hundreds of diseases sharing common features. We argue that exploiting shared features among diseases is fundamental for achieving high accuracy in prioritizing disease-genes. To this end, we compared several state-of-the-art semantic similarity measures among nodes in a hierarchy (like MeSH terms), including measures depending on the hierarchy structure, measures depending on the disease information (known disease-genes), and their combination. In addition, by leveraging diseases similarities we have been able in inferring putative associations for more than 800 MeSH diseases, including around 400 diseases with no discovered genes, thus overcoming the main limitation of existing methods.
We validated our method on benchmark data including nine human gene networks, containing 8449 genes and 708 MeSH disease terms, with statistically significant improvements over benchmark methods. In order to supply reliable novel gene-disease associations, we then constructed an enriched data set by integrating existing networks with the STRING network, version 10.0 [45] , and by downloading recent human gene association for MeSH diseases from the Comparative Toxicogenomics Database (CTD) [46] . The obtained data contain 19112 human genes and cover diseases at different levels of specificity and spanning different general categories of MeSH diseases.
Overall, the main contributions of this study are summarized as follows:
(i) A novel and flexible framework Gene2DisCo to prioritize genes not dependent on specific sources of data and/or of gene-disease annotations and composed by the following modules (see Figure 1 ): a module to integrate different and heterogeneous network-based data sources; 2) a module to embed information about diseases similar to the disease under study; 3) a module to infer imbalance-aware predictions on the basis of input data, including data provided by modules 1 and 2. (ii) A comparative analysis of different methods to compute pairwise semantic similarities among diseases and a quantitative evaluation of their impact on gene prioritization. (iii) One of the widest data set for prioritizing genes, involving gene-MeSH disease associations covering hundreds of diseases, and extended to the whole human genome. (iv) The inferred predictions for around 800 MeSH diseases, including 348 diseases without known causal genes.
This paper is organized as follows. In Section 2 we describe the benchmark data used to validate Gene2DisCo and the refined data set embedding the STRING network. Section 3 discusses the GP problem, the data integration procedure, the disease similarity measures adopted, and the generalized linear model proposed to solve the GP problem. The experimental setting and validation, and the top-ranked unannotated genes for the considered MeSH diseases are presented in Section 4. The conclusion remarks end the paper.
Materials
We present here the networked data sources adopted to prioritize genes. In particular, we first describe the benchmark data set utilized to validate our method, and then we propose an enriched data setting extended to the whole human genome and including more recent gene-disease associations.
Benchmark data
We follow the benchmark setting proposed in [47] , which includes nine human gene networks covering 8449 genes (or a subset of them), and the associations of such genes with 708 selected MeSH disease terms, downloaded from the CTD database. MeSH is a vocabulary thesaurus, being controlled by the National Library of Medicine to index MEDLINE documents, which consists of a set of description terms organized in a hierarchical structure (called MeSH trees), where more general terms appear at nodes closer to the root and more specific terms appear at nodes closer to leaves [48] . Each MeSH node is represented by a tree number, which indicates the position of the node in MeSH tree. Furthermore, every MeSH heading may correspond to more than one node in different MeSH trees (or subtrees). Finally, each tree in the MeSH hierarchy belongs to a semantic category, among which the headings considered in this work fall into categories C -Diseases and F -Psychiatry and Psychology.
The benchmark nets cover different types of information: functional interactions, transcriptional co-expression/regulation and localization, gene expression profiles, genes-chemicals relationships, protein-protein physical and genetic interactions (2 networks), Gene Ontology (GO) [49] semantic similarity (3 networks). The benchmark MeSH terms posses between 5 and 200 annotated genes, thus avoiding to consider both diseases with too few available information and diseases with a large and heterogeneous set of associated genes (since a gene annotated with a term is also annotated with its ancestors). A brief description of every gene network is supplied below.
Functional interaction network -finet. Composed of 8441 selected proteins, this net contains protein-protein functional binary interaction inferred through a Naive Bayes classifier, trained by using information coming from expertcurated biological pathways and from other non curated sources, such as gene co-expression and protein domain interaction [50] .
Human net -hnnet. Starting from 21 large-scale genomics and proteomics data sets from four species, in [51] [53] , and including 8449 proteins.
BioGRID projected network -bgnet. This net relies on the construction of a bipartite graph by using physical and genetic BioGRID interactions between the benchmark 8449 genes and all the human genes available in BioGRID. The net is pruned to the benchmark genes by inserting and edge between two genes if they share at least on neighbour in the bipartite graph.
Semantic similarity-based networks: bpnet, mfnet and ccnet. For every branch (biological process, molecular function and cellular component ) of GO taxonomy, a net is constructed by considering the GO terms the 8449 genes are annotated with, and by setting an edge between two genes if they share at least one annotation in the corresponding GO branch. The edge weight is the maximum Rensik semantic similarity [54] between all the terms for which the two genes are both annotated.
Refining benchmark data
We then constructed a novel data set, including a larger set of human genes and current and more reliable gene-disease associations. We retrieved the input network from STRING database, version 10.0 [45] , including all the available genes and their pairwise interactions to maximize the coverage. This network is highly informative, since STRING curators already merge several sources of data, including protein homology relationships from different species. Moreover, in order to enrich the information encoded into the obtained network, we also integrated by unweighted sum the networks described in Section 2.1 (on the union of genes, see Section 3.2), excluding the network gcnet which is biased toward MeSH disease terms, as explained in [44] . The final network covers 19112 genes and has around 5.9 millions of distinct edges.
We downloaded the gene-disease associations from the CTD database (04.17), obtaining is a set of 470 MeSH disease terms with 2-200 positive genes, of which 437 posses at least 5 known associations. We excluded diseases with more than 200 associations in order not to work with too generic terms in the MeSH ontology; on the other side, we included diseases with less than 5 associations to work even with more specific (and/or less studied) diseases, exploiting the ability of Gene2DisCo to transfer information from similar diseases. The enriched STRING net and the corresponding MeSH associations are available at http://frasca.di.unimi.it/data/gene2disco/.
Methods
This section is devoted to illustrate the automated methodologies we adopted to solve the gene prioritization problem. First, we introduce some preliminary definitions, and provide the details of a state-of-the-art method, NWGP, recently proposed for prioritizing genes; then, we describe our proposed methodology extending NWGP to embed disease pairwise similarities into the model.
The problem
The gene prioritization problem can be cast into the framework of learning node labels in partial labeled graphs. In this context, a gene network can be represented through an undirected weighted graph G = (V, W ), where V = {1, 2, . . . , n} is the set of vertices corresponding to genes, and W is the n × n weight matrix, where each element W ij ∈ [0, 1] represents some notion of functional similarity between vertices i and j. Vertices in V can be partitioned into two subsets: L ⊂ V containing instances labeled according to a specific class (MeSH disease term in our context), and its complement U = V \ L which, including unlabeled instances, represents the object of our inference. The set of labeled vertices is further partitioned, according to the labeling vector l ⊂ {−1, 0, 1} |V | , in the sets L + := {i ∈ L|l i = 1} and L − := {i ∈ L|l i = −1} of the positive and negative vertices respectively. Here we assume unlabeled instances posses label 0, denoting the notion of 'no available information'. Furthermore, the labeling l is subjected to a severe imbalance in favor of negative instances, that is |L + | ≪ |L − |.
The gene prioritization problem, which falls in the realm of Label Prediction in partially labeled Graphs (LPG), consists in learning a function φ : U → R ranking unlabeled genes/vertices so as to assign higher positions to instances candidate for the positive class. The function φ, suitably thresholded, can be then used to assign positive or negative labels to unlabeled vertices.
Graph integration
The q = 9 graphs
) corresponding to the nets described in Section 2 have been integrated in a unique composite graph G = (V, W ) by taking the union of all genes, as done in the benchmark setup. After having extended each graph to the union V of vertices by adding zeros in the missing entries of the corresponding adjacency matrix, to integrate them we adopted the unweighted sum integration, which performed better than other unweighted schemes used in the benchmark setting. Informally, it consists in averaging the adjacency matrices of all available graphs, that is
The Laplacian normalization is finally applied to the integrated network W * obtaining the matrix
, where D is the diagonal matrix of node weighted degrees.
Disease semantic similarities
As mentioned in Section 2.1, MeSH disease terms are structured as a hierarchy and thereby not independent from each other, and accordingly a disease may share more features with some diseases and less or none with the remaining diseases. For this reason, here we investigate several ways to compute pairwise similarity measures among diseases. In the following we recall the main stateof-the-art approaches for computing similarities among nodes in a hierarchy, dividing them in two categories: path-based, using solely the hierarchy structure, and information-based, using the information at each disease (the genes known to be involved in the disease) alone or along with the disease hierarchy information.
Basic definitions. In general, a disease hierarchy may posses different structures (forest of trees like MeSH hierarchy, direct acyclic graph like the Human Phenotype Ontology [55] , etc.) and can be represented by a graph H = (C, E), where C = {1, 2, . . . , m} is the set of nodes/headings, E is the set of hierarchical relationships among nodes. The aim is determining a matrix Ψ ∈ R m×m of pairwise node similarities. Before describing several ways proposed in the literature to compute Ψ, we introduce some definitions used throughout the paper. By anc(k) ⊂ C we denote the set of ancestors of node k ∈ C, and by lev k we denote the level of k in the hierarchy, intended as the number of nodes on the maximum length path from a root node. The level of a root node is thereby 1. To facilitate the following discussion, we assume a unique root in present in H. As in a graph we might have multiple roots, we assume in this case a dummy node is added as parent of root nodes. Moreover, we use ν(k) to denote the frequency of positive instances for node k and l (k) to denote the labeling vector for node/disease k (see Section 3.1). Since parent-child connections describe specializations of the parent node, a positive instance for a node k must be positive even for any r ∈ anc(k). Hence it holds that ν(k) ≤ ν(r) for any r ∈ anc(k). Finally, we denote by MA(k, r) the common ancestor of nodes k, r ∈ C whose frequency ν(MA(k, r)) is the lowest among all ancestors of both k and r.
We describe now the main approaches proposed in the literature for computing semantic similarities in a hierarchy, diving them in two main categories: path-based similarity measures, exploiting solely the hierarchy structure, and information-based similarity measures, leveraging the information content of nodes.
Path-based similarity measures. A first category of methods compute similarity between two nodes as a function of the length of the path linking the nodes, and/or on their position in the hierarchy. In particular we distinguish the following:
SP: Shortest Path [56] . This measure is based on the simple observation that the closer two nodes k, r ∈ C, the more similar they result. This measure is computed through the ratio of the shortest path sp(k, r) between k and r, and the maximum path length between two nodes in C:
Thus, 0 ≤ ψ SP (k, r) ≤ 1, and the most distant nodes have similarity 0.
Here sp(k, r) is the function associating nodes k and r with the length of their shortest path (the path weight is the number of edges on the path).
WL: Weighted Links [57] . This measure extends the SP measure by assigning weights to paths depending on the depth of nodes forming the path. The weight of a node k ∈ C is the reciprocal of its level in the hierarchy. Thus:
where wl(k, r) is the function associating nodes k and r with the weight of their shortest path (s 1 , s 2 , . . . , s n kr ), that is wl(k, r) =
1 /levs i .
WP: Wu and Palmer [58] . Considering the nearest common ancestor NA(k, r) of two nodes k, r ∈ C, it computes:
The lowest similarity between two nodes is obtained when their common ancestor is the root node, and they posses a high level.
LC : Leacock and Chodorow [59] . This measure differs from ψ SP in sense that it takes the logarithm of the resulting score plus a pseudocount:
Li : Li et al. [60] . Intuitively and empirically derived, it combines the shortest path and the level of the nearest common ancestor in a non-linear function, as follows:
where α and β are real parameters weighting the contribution of the shortest path length and level respectively. According to [60] , we set α = 0.2 and β = 0.6.
Information-based similarity measures. Let − log(ν(k)) be the information content of node k ∈ C. Several measures of similarity have been proposed in the literature exploiting information contents of nodes, with or without considering the hierarchy structure. Here we describe those adopted in this work.
Lord : Lord et al. [61] . This measure is based on the frequency of the common ancestor with the lowest frequency:
Hence two nodes tend to be more similar when their minimum common ancestor has a low frequence (thus more specific).
Resnik : Resnik [54] . The similarity of two nodes is the information content of their minimum common ancestor:
Lin : Lin [62] . Given two nodes k, r ∈ C, their similarity is the ratio of the information content of their closest common ancestor MA(k, r) (their commonalities) and the sum of the information content of k and r (all information needed to describe k and r):
JC : Jiang and Conrath [63] . The similarity between nodes k, r ∈ C is based on the following distance:
The distance Dist is usually used to get the corresponding similarity as follows:
Jaccard: Jaccard [64] . Given nodes k, r ∈ C, their Jaccard similarity is:
This is the ratio between the number of genes that are positive for both nodes and the number of genes that are positive for at least one node. The higher the number of shared genes, the higher the similarity (up to 1). When two nodes do not share any gene, their similarity is zero. In a disease hierarchy, diseases with many positive instances are usually closer to the root (less specific). In this case, the denominator of ψ Jaccard tends to reduce the similarity between the two diseases as opposed to the case in which diseases have a small number of associated genes. Indeed, sharing positives between two specific diseases (closer to leaves) is more informative than sharing positives between two more general diseases (closer to the root).
Algorithmic scheme
Recently, an effective approach NWGP to gene prioritization exploiting generalized linear models (GLMs) for solving the LPG problem has been proposed [44] . In this method, which extends a previous approach WGP [43] , the response variable decrees the membership to either the positive or negative class (causative and non causative genes). We retain GLMs suitable for LPG mainly for three reasons: (i) the need to keep the computational burden low, so as to efficiently deal with the large size of processed data; (ii) their ability to cope with unbalanced labelings (like in our context) by assigning different misclassification costs to positive and negative instances when learning the model; (iii) the easy interpretability of the results characterizing GLMs.
NWGP algorithm adopts a selection of appropriate features associated with vertices/genes able to speed-up the process and to retain the information for an accurate classification: it adopts 2 features, selected in order to suitably represent the local imbalance information at each vertex. Nevertheless, while this algorithm predicts gene-disease associations for a disease independently from the other diseases, here we argue that the semantic relatedness among diseases may strongly help the process of gene prioritization.
In the following we first shortly describe the NWGP approach, then we focus on our novel approach to overcome some limitations of NWGP by embedding in the model the disease-disease relatedness information.
NWGP:Negative Selection for Weighted Gene Prioritization
The first step of this algorithm associates with each vertex i ∈ L a point
in the plane, where:
This projection allows to avoid the curse of dimensionality problem, since the projected space only has two dimensions, and to handle the class imbalance problem by assigning different misclassification costs to positive and negative points during the learning phase. Then a negative selection procedure is applied to retain solely the reliable negative points during the learning (we recall that in the MeSH taxonomy solely positive associations are stored). This procedure performs a fuzzy clustering of positive points P + = {∆ i |i ∈ L + } [65] , and then it scores negative points P − = {∆ i |i ∈ L − } according to their maximum membership to the h found clusters:
where c 1 , . . . , c h are the cluster centroids, d denotes the distance function used by the fuzzy C means (FCM) algorithm [66] , and α is a free fuzzification parameter. In the rest of this paper we adopt the L3 distance, which performed slightly better than the other distances tested in [44] . The scores associated through σ to negative points are used to: 1) discard negatives whose membership is higher than a given threshold τ (set as the z-quantile of the empirical distribution of the memberships), obtaining novel sets of negative instancesL − = {i ∈ L − |σ(∆ i ) > τ } and of negative points P − = {∆ i |i ∈L − }; 2) assign weights to the training instances as follows:
Authors learned several GLMs by using the computed weights (10) to separate the selected positive and negative points P + ∪P − , with the complementary log-log link function showing the best performances (see [44] for details). Following the suggestions in [44] , in this work we set z = 0.5, that is half of negative points is discarded.
Learning limitations of NWGP
Intuitively, through the projection shown in Eq. (8), the more a vertex i is functionally similar to positive labeled vertices, the higher the value of ∆ + i , and analogously for the contribution given by negative labeled vertices to the second coordinate. Remembering the one-to-one correspondence between genes and vertices, with this projection the aim is to find a bipartition of vertices in L which concentrates positive points mostly toward the rightmost lower region of the first quadrant, and the negative points in the rest of the same area. The meaningfulness of such partition relies in turn on the extent to which the set of positive (resp. negative) genes satisfies the two clustering properties of showing high functional similarity with the other genes in the same class and low similarity with genes negatively (resp. positively) labeled as well.
Unfortunately, as evident from Figure 2 (a-b), depicting two typical instances of the LPG problem downline of the above projection (MeSH ID D003555, C565836 respectively), there is no clear distinction between positive and negative points. Actually, the former are indeed located toward the right extreme of the horizontal axis, contrarily to the negative instances which are distributed in a wider region of the plane; however, both are so intimately mixed up that, in principle, it would be very difficult to distinguish the two classes with a generalized linear model, unless non negligible effects of the two-way interaction between ∆ + and ∆ − are observed. Two this end, in Figure 2 (c-d) we enriched the same instances shown in Figure 2(a-b) by adding a third coordinate in terms of the interaction term ∆ + ∆ − . Nevertheless, we do not observe a significant improvement of the ability in the discriminating positive and negative points in the new space, since the shape became glancing convex but points still mixed up. This means that the newly added coordinate would not significantly help the classification ability of the model.
We further show this in the following discussion. With reference to labeled vertex i, let us denote with x i1 and x i2 the coordinates ∆ (α 0 , α + , α − , α ± ) the vector of regression coefficients, Figures 3(a-b) show how the linear model:
is able to discriminate between positive and negative labeled nodes in the two lead examples considered so far, distinguishing their labels through a different color. To visually understand the discriminative power of the model, in Figures 3(c-d) we show the curves representing the best learned separators, where points located above (resp. below) the separator will receive a positive (resp. negative) label; it is evident the suboptimal nature of the separating profile, with the majority of positive points wrongly classified. We recall that in this context positives carries almost all the available information.
In conclusion, even adding a the further feature ∆ + ∆ − (x 1 x 2 ), projected points still were located so as to make difficult the separation of positive and negative classes. This is likely due to the fact that the third feature we added is related to the other two features; in the next section we show how the semantic contribution of ontologically related diseases can be used to define a novel third feature for the model, able in increasing the discriminative power while preserving the computational efficiency.
Generalized linear models embedding disease relatedness: Gene2DisCo
We introduce in this section Gene2DisCo (Gene to Disease using Disease Commonalities), an algorithm extending NWGP to transfer information from similar diseases when prioritizing genes according to the disease of interest.
As discussed in Section 3.3, we assume diseases are structured as a graph H = (C, Ψ), where the Ψ = ψ kr | |C| r,k=1 is the disease similarity matrix, and ψ kr := ψ X (k, r) ≥ 0, with X denoting one of the disease similarity measures described in the same section.
To appropriately define the third coordinate of our model, we first focus on which characteristics such coordinate must possess. Intuitively, we expect that the third coordinate x (k) i3 for gene i and disease k, embedding information from diseases related to k, respects the following simple properties:
i3 is larger when the gene i is already associated with another disease similar to k, matching the idea that when a gene is known being involved in a disease sharing different profiles (toxicological, genetic, phenotypic and so on) with another disease, that gene is more likely to have a role even in the latter disease; (ii) the larger the number of diseases similar to k the gene i is associated with, the larger x 
+ . Finally, the matrix containing the characteristic vectors of diseases C is denoted by L = (χ (+,1) , . . . , χ (+,m) ). The disease semantic relatedness coordinate for a gene i ∈ V when predicting a disease k ∈ C is the following:
where ' · ' is the dot product in the Euclidean space R m . L i· is thereby the positive labeling of gene i for all considered diseases, and Ψ ·k is the vector of similarities between the disease k and the other diseases.
It is straightforward showing that the four prerequisites (i), (ii), (iii), (iv) are satisfied by the definition (12) (the proof can be easily obtained by the definitions of dot product and of the vectors L i· and Ψ ·k ). Importantly, in order not to introduce bias in the procedure, when computing x i3 we exclude descendants r of disease k in the MeSH hierarchy (that is k ∈ anc(r)), since descendant terms are subsets of their ancestors (see Section 3.3). Furthermore, it may happen, mainly when diseases have few positive genes, that two different but related diseases have exactly the same positive genes (we also experimentally found it in data described in Section 2). Although this would not be a bias but an advantage of our method, in order to have an idea of the performance when all diseases posses different labelings, in our validation experiments we also discarded diseases having exactly the same positive genes of disease k. Hence, the performance of Gene2DisCo shown in Sections 4.1 and 4.2 are suboptimal. Instead, to provide predictions as much reliable as possible, we exploited all diseases when inferring novel candidate disease-genes (see Section 4.3).
To investigate whether this novel feature is really able to improve the discriminative power of our generalized linear models, in Figure 4 we graphically visualize points with coordinates (x 1 , x 2 , x 3 ) as done in Figure 3 (a-b) for the two MeSH diseases taken as example, and then draw the best linear regression model separating positive and negative points. We omit by purpose the superscript (k) to simplify the notation.
Interestingly, the added coordinate x 3 (computed using the Jaccard similarity) moves the majority of positive points above negative points: indeed, most negative points still lie nearby the (x 1 , x 2 ) plane. The learned model now correctly classifies almost all positive points (especially for the example (b)), and positives located below the separator plane however lie not far from it. This is better shown by the residuals of positive points (vertical lines): they are positive in the majority of cases (which means a positive point correctly classified), and the negative residual (corresponding to misclassified positives) have in average a smaller magnitude than the positive residuals. We remark that the two MeSH disease terms shown in this example are representative of a general behavior observed even for the other diseases. As assessed in the next section, the effectiveness of this novel feature is also experimentally confirmed.
Overall, the pseudocode of Gene2DisCo algorithm is shown in Figure 5 . Lines 1-4 computes the node projection onto R 3 , whose time complexity is O(n 2 + nm) = O(n 2 ) (which becomes O(n) when W is sparse, like in our context), whereas line 6 performs the fuzzy clustering, taking time
, where I 1 the number of iterations in one run of the clustering algorithm. With complexity O(n) lines 9-12 calculate the instance weights for the misclassification costs to be used in the GLM training, which is performed at line 13. The cost of training GLM model training depends on the number of iterations I 2 to convergence of the iterative reweighted least square algorithm [67] , each one with complexity (considering the weighted least square solution) O(
, since m = 3 and h limited by the number of positives. The source code of Gene2DisCo can be found at http://frasca.di.unimi.it/data/gene2disco/. Input:
for each i ∈ V do 02:
end for 05:
for each i in {L
11:
end for 13:
− , ω, link = Cloglog) end algorithm Output: the ranking function φ and the predicted scores φ(∆ i ), i ∈ U .
Results and discussion
Gene2DisCo has been experimentally validated by following the benchmark setting proposed in [47] , thus allowing its fair comparison with the benchmark methodologies (described in the next section). Namely, such setting adopts the k-fold cross-validation (CV) procedure (k = 5) to assess the generalization abilities of the compared methods, and the Area Under the ROC Curve (AUC) and the Precision at different Recall levels (PXR) to measure the corresponding performance. Furthermore, as done by authors of NWGP on the same data, we also computed for our method the Area Under the Precision-Recall Curve (AUPRC), being AUPRC more informative than AUC on unbalanced settings [68] .
The benchmark methods adopted in [47] are the following: GBA, family of algorithms relying upon the guilt-by-association rule, which allows making predictions exploiting the interacting genes, under the assumption that interacting genes are likely to share similar functions [69, 70] ; RW, random walks algorithm [71] ; RWR, random walks with restart which takes into account that after many steps the walker may forget the prior information coded in the initial probability vector, and accordingly the algorithm allows the walker to restart from its initial condition with a given probability θ (free parameter), or to move another random walk step with probability 1 − θ; kernelized score functions, extending the similarity to non neighboring nodes by adopting a suitable kernel matrix [72] . The score for each gene i with regard to a given disease r is defined according to a suitable distance d(i, V r ) between i and the subset V r of positive genes for r. By varying the definition of d(i, V r ) authors obtained different scoring methods, among which the top performing was S AV : d(i, V r ) is defined as the average distance between the images in the corresponding Hilbert space of i and V r . The kernel used is K t obtained by a t-step (t = 1, 2, . . .) random walk,
, I is the n × n identity matrix, γ > 0, and D is a diagonal matrix whose diagonal elements are the sums of the corresponding rows in W .
As baseline comparison, in this paper we report just the performance of the top benchmark method (S AV t = 5). Furthermore, we compare our method also with the NWGP algorithm.
Evaluation on benchmark data
We dedicate this section to the comparison of our method with benchmark methods described above, and to the evaluation of the impact the different disease similarity measures described in Section 3.3 have on the Gene2DisCo performance. To this end, we have constructed other six similarity measures by integrating the considered measures through the unweighted sum (US) integration and the Max integration, defined as follows. Given s disease similarity matrices Ψ (1) , . . . , Ψ (s) , the unweighted sum integration is
whereas the Max integration is obtained by setting each entry of the integrated matrix as the maximum value of that entry in the single matrices:
We employed both schemes in three different integrations: (ALL) integration of all considered measures; (InfoSim) integration of information-based measures only; (PathSim) integration of solely path-based measures. Figure 6 shows the corresponding results. To facilitate distinguishability among methods, bar colors have been grouped according to the type of diseases semantic similarity: pathbased, information-based, US and Max similarity measures are respectively in blue, turquoise, green and brown scale colors. Firstly, results have an analogous trend for both AUC and AUPRC measures, with most measures showing similar performance. The only exception is the Jaccard similarity, which largely achieves the best results (Wilcoxon signed rank test, p-value < 0.001) in both performance metrics, especially in terms of AUPRC, which is more relevant in this context (rare positives). Such an advantage for the Jaccard similarity also confirms results obtained in [73] . Gene2DisCo outperforms NWGP in both AUC and AUPRC, with any disease semantic similarity metric adopted, mainly in terms of AUPRC, showing the noticeable benefit of transferring information from similar diseases. Indeed, the improvement when using the Jaccard similarity is impressive: 0.1917 for NWGP and 0.3899 for Gene2DisCo, more than the double. By reminding AUPRC measures the area under the Precision and Recall curve, this means in particular that the ability of our method in classifying positives is considerably improved with reference to NWGP : in the gene prioritization context, this corresponds to a better ranking of disease-genes, which is exactly the final aim of gene prioritization. Even S AV t = 5 is largely outperformed by Gene2DisCo in terms of AUC (we remind that in the benchmark setting, AUPRC was not computed). This behaviour is confirmed by the PXR results in Figure 7 : all Gene2DisCo variants lie above both S AV t = 5 and NWGP, with larger improvements for smaller Recall values, which are more important in context with scarcity of positives. Even in this case, the Jaccard variant performs best among Gene2DisCo variants, for all the Recall values considered.
Finally, Gene2DisCo takes around 7 seconds to perform a 5-fold CV procedure for a single MeSH disease term on an Intel i7-860 CPU 2.80 GHz machine with 16 GB of RAM, including the computation of Jaccard similarity on the training data. Hence, passing from 2-to 3-dimensional space just slightly increased the overall computational complexity of the GLM training, considering that NWGP in the same setting, but without the computation of the Jaccard similarity, takes around 5 seconds.
Results on refined benchmark data
Although our aim on the enriched data set is to infer novel candidate diseasegenes, since we have already validated our method in the Section 4.1, to facilitate possible comparisons with other methodologies, in Table 1 we report the average results obtained through a 5-fold cross validation in predicting the 470 selected MeSH disease terms in the refined benchmark data described in Section 2.2. It is interesting to observe that the quality of Gene2DisCo predictions, with reference to results shown in Section 4.1, is maintained even in this setting with more genes and higher complexity (stronger labeling imbalance). Moreover, to better analyze the behaviour of Gene2DisCo, we distinguished average results across the two categories of diseases with 5-200 and 2-4 disease-genes. Interestingly, the performance in the former category of diseases, those having less available information, is not affected by a large overall decay: an average AUPRC value 0.268 is remarkable for diseases with very rare positives. 
Providing novel putative gene-disease associations
This section is dedicated to provide predictions for novel candidate genedisease associations. Since our method can be also exploited to predict diseases with one or zero known disease-genes, we included in our setting also such diseases, in addition to those described in Section 2.2. We did not considered these diseases in the previous section because they cannot be used in cross validation procedures, since positives (disease-genes) are not enough. Specifically, we selected: 1) diseases with at most 200 genes associated with; 2) diseases without known gene associations but sharing non null disease commonalities with at least one disease with positives (348). We adopted the Jaccard similarity (which performed best) for the diseases with positives, and the sum integration of path-based similarity measures (Jaccard is not applicable, see Section 3.3) for diseases without positives.
We obtained a set of 842 MeSH disease terms, spanning all the different levels in the hierarchy except for level 1 (root nodes, we remind that the level is the number of nodes on the path corresponding to the maximum distance from a root node). The empirical distribution across node levels is reported in Table 2 . Furthermore, the selected diseases cover different MeSH trees, whose roots are shown in Table 3 , with the corresponding description. The total number of diseases in that table is larger than 842 because some MeSH headings fall in more than one tree.
To infer the gene ranking for MeSH disease terms without annotated genes, we could not learn the GLM model because there are no positives; accordingly we used the inter-disease score in formula (12) to determine an association score for gene i and disease k. The obtained score matrix A = L · Ψ can be downloaded at https://frasca.di.umimi.it/gene2disco/. In order to facilitate interpreting such predictions, we selected for every disease the three top-ranked genes. Since the inferred score may depend on the number of diseases a gene is already associated with (see formula 12), we added a further processing step for determining the desired list:
1. For every k ∈ {1, 2, . . . , m}, sort each row A i. in decreasing order 2. Determine the rank r (k) i of disease k in the obtained vector 3. Select the genes corresponding to the three highest ranks in the vector r k , that is the genes for which disease k was ranked atop the other diseases For diseases with known associations, we adopted the GLM prediction as discussed in Section 3.4.3 to determine the top three genes for every disease. In order to provide the most reliable predictions, a more intensive procedure has been adopted. Namely, we used all the positive genes available to train the model, and randomly partitioned negative genes in ten subsets, using nine of them together with positives for training a model to predict the remaining subset. The procedure has been iterated ten times, one for every subset of negatives. All inferred predictions and selected candidate disease-genes can be found at https://frasca.di.umimi.it/gene2disco/.
As further validation, we ran multiple independent runs of the cross validation procedure and computed the inferred putative associations confirmed in each run. To investigate the most specific descriptions and more reliable predictions, we considered the MeSH disease terms with the highest performance in all the runs and with at most 10 positive genes. Moreover, in the obtained associations we further filter out those involving genes with high node degree in the network, being node degree a proxy for gene multifunctionality and thus leading to more generic associations [74] . The suggested candidate disease-genes are shown in Table 4 . Interestingly, the protein coding ABCB1 (ATP binding cassette subfamily B member 1) and ABCC6 (ATP binding cassette subfamily C member 6) belong to the same superfamily of ATP-binding cassette (ABC), and multiple studies have already associated ABCC6 with Angioid Streaks [75, 76, 77] . The protein coding gene ILB1 (interleukin 1 beta) is a member of the interleukin family, to whom belong the interleukins IL12B IL5RA, IL3, IL5 having curated associations with Central Serous Chorioretinopathy at CTD database (04.17). Gene CYP3A4, encoding a member of the cytochrome P450 superfamily of enzymes, is already associated with Delirium [78] , Depressive Disorder [79] , and Bipo-lar Disorder [80] , diseases sharing therapeutic chemical profiles with Psychoses, Alcoholic (CTD disease comp, update 04.17). Moreover, gene IL1F7 is a member of the same family of two genes, IL1A and IL1B, actually associated with Olfactory Nerve Injuries [81] . Finally, gene CASR (calcium sensing receptor) is involved in Hyperparathyroidism, Primary disease, which shares chemical interaction profiles (via Lithium Carbonate, CTD disease comp, update 04.17) with Diffuse alopecia disease.
Conclusions
This work showed that disease relatedness is a fundamental feature of the gene prioritization (GP) process, and that GP methods must exploit commonalities among diseases to achieve more reliable predictions. We have developed a network-based approach, named Gene2DisCo, for prioritizing genes associated with a given disease, whose main contributions are the following: (i) the construction of a framework aware of several issues characterizing the gene prioritization process, including the need of integrating different data sources, the rarity of known diseases-genes, and the existence of common profiles among different diseases; (ii) the derivation of a method based on generalized linear model (GLM) embedding disease pairwise similarities; (iii) the extensive comparison of several state-of-the-art semantic measures to compute semantic similarity among diseases. With this novel technique, our method performed much better than a set of state-of-the-art methodologies for disease-gene prioritization on a benchmark dataset and than an existing technique based on GLM using exactly the same input information as Gene2DisCo, but neglecting information from similar diseases. Unlike existing approaches, a main feature of Gene2DisCo is the capability of inferring gene prioritization lists even for diseases without known causative genes. This study also made available a novel benchmark dataset for future comparison providing gene-gene connections extended to the whole human genome, and recent genes-disease associations retrieved from the Medical Subjects Headings (MeSH) ontology. Finally, exploiting the ability of Gene2DisCo in enriching the information available for diseases with few or none associations, we provided a set of three top-ranked candidate genes for 842 MeSH diseases with 0 up to 200 known gene associations.
